SCHEMBL25545940

SCHEMBL25545940

CCOc1cccc(-c2nc(Cl)sc2CC(C)(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.44
KMT2A Q03164 2/20 0.44
BRD4 O60885 1/20 0.41
BRD2 P25440 1/20 0.41
CREBBP Q92793 1/20 0.41
S1PR1 P21453 4/20 0.41
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
TP53 P04637 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 3/20 0.40
MAPT P10636 3/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 2/20 0.40
RAB9A P51151 2/20 0.40
MAPK1 P28482 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25546008 0.87 IGF1R (0.39) KMT2ASMN1; SMN2KDM4EMAPTMEN1
SCHEMBL25546340 0.85 NOTUM (0.46) NOTUMKMT2ABRD4BRD2CREBBP
SCHEMBL25546032 0.83 KMT2A (0.47) NOTUMKMT2ABRD4BRD2CREBBP
SCHEMBL25546322 0.81 NOTUM (0.43) NOTUMKMT2ABRD4BRD2CREBBP
SCHEMBL25180286 0.81 GRM2 (0.41) KMT2AALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL25556504 0.79 ALDH1A1 (0.37) KMT2AS1PR1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL25546017 0.79 ALDH1A1 (0.37) KMT2AALDH1A1KDM4EMAPTFGFR2
SCHEMBL25556506 0.76 XDH (0.38) KMT2ABRD4ALDH1A1SMN1; SMN2KDM4E
SCHEMBL25546406 0.76 CHEK1 (0.40) NOTUMKMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL25546356 0.74 KDM4E (0.46) KMT2AALDH1A1SMN1; SMN2TP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 NOTUM 3220/4885KMT2A 1931/4885BRD4 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.